

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

Brilliant Violet 785(TM) anti-human CD45RA

RRID:AB_2563816

Type: Antibody

Proper Citation

BioLegend Cat# 304140, RRID:AB_2563816

Antibody Information

URL: http://antibodyregistry.org/AB_2563816

Proper Citation: BioLegend Cat# 304140, RRID:AB_2563816

Target Antigen: CD45RA

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD45RA

Description: This monoclonal targets CD45RA

Target Organism: human

Clone ID: Clone HI100

Antibody ID: AB_2563816

Vendor: BioLegend

Catalog Number: 304140

Alternative Catalog Numbers: 304139

Record Creation Time: 20231110T035212+0000

Record Last Update: 20260901T045030+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD45RA.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD45RA.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Jones RD, et al. (2026) Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells. *Cell stem cell*, 33(1), 73.

La C, et al. (2026) In vivo modeling of human ?? T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 V?2 T cell development. *Cell reports*, 45(2), 116977.

Marciello I, et al. (2025) Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry. *STAR protocols*, 6(2), 103775.

Tzeng SF, et al. (2025) PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis. *Cancer discovery*, 15(8), 1676.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. *Frontiers in immunology*, 16, 1609658.

David M, et al. (2025) Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs. *Molecular therapy. Oncology*, 33(2), 200989.

Wagoner ZW, et al. (2025) Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. *Cell stem cell*, 32(4), 529.

McCallion O, et al. (2024) Regulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants. *Med (New York, N.Y.)*, 100561.

Dyikanov D, et al. (2024) Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. *Cancer cell*, 42(5), 759.

Kastenschmidt JM, et al. (2023) Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. *Immunity*, 56(8), 1910.

Ritacco C, et al. (2023) Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. *iScience*, 26(3), 106085.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer cell*, 40(8), 879.

Vanshylla K, et al. (2022) Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. *Cell host & microbe*, 30(1), 69.

Ranzoni AM, et al. (2021) Integrative Single-Cell RNA-Seq and ATAC-Seq Analysis of Human Developmental Hematopoiesis. *Cell stem cell*, 28(3), 472.

Argüello RJ, et al. (2020) SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution. *Cell metabolism*, 32(6), 1063.

Weisberg SP, et al. (2019) Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway. *Cell reports*, 29(12), 3916.